Asthma and rhinitis control in adolescents and young adults: A real‐world MASK‐air study
Bernardo Sousa‐Pinto,Arunas Valiulis,Erik Melén,Gerard H. Koppelman,Nikolaos G. Papadopoulos,Mika Makela,Tari Haahtela,Matteo Bonini,Fulvio Braido,Luisa Brussino,Alvaro A. Cruz,Alessandro Fiocchi,Mattia Giovannini,Bilun Gemicioglu,Marek Kulus,Piotr Kuna,Maciej Kupczyk,Violeta Kvedariene,Désirée E. Larenas‐Linnemann,Renaud Louis,Mario Morais‐Almeida,Marek Niedoszytko,Markus Ollert,Oliver Pfaar,Frederico S. Regateiro,Graham Roberts,Boleslaw Samolinski,Marine Savouré,Luis Taborda‐Barata,Sanna Toppila‐Salmi,Maria Teresa Ventura,Marta Vazquez‐Ortiz,Rafael José Vieira,Joao A. Fonseca,Arzu Yorgancioglu,Torsten Zuberbier,Josep M. Anto,Jean Bousquet,Nhân Pham‐Thi,the MASK‐air think tank
DOI: https://doi.org/10.1111/pai.14080
2024-02-03
Pediatric Allergy and Immunology
Abstract:Background In allergic rhinitis and asthma, adolescents and young adult patients are likely to differ from older patients. We compared adolescents, young adults and adults on symptoms, control levels, and medication adherence. Methods In a cross‐sectional study (2015–2022), we assessed European users of the MASK‐air mHealth app of three age groups: adolescents (13–18 years), young adults (18–26 years), and adults (>26 years). We compared them on their reported rhinitis and asthma symptoms, use and adherence to rhinitis and asthma treatment and app adherence. Allergy symptoms and control were assessed by means of visual analogue scales (VASs) on rhinitis or asthma, the combined symptom‐medication score (CSMS), and the electronic daily control score for asthma (e‐DASTHMA). We built multivariable regression models to compare symptoms or medication accounting for potential differences in demographic characteristics and baseline severity. Results We assessed 965 adolescent users (15,252 days), 4595 young adults (58,161 days), and 15,154 adult users (258,796 days). Users of all three age groups displayed similar app adherence. In multivariable models, age groups were not found to significantly differ in their adherence to rhinitis or asthma medication. These models also found that adolescents reported lower VAS on global allergy, ocular, and asthma symptoms (as well as lower CSMS) than young adults and adults. Conclusions Adolescents reported a better rhinitis and asthma control than young adults and adults, even though similar medication adherence levels were observed across age groups. These results pave the way for future studies on understanding how adolescents control their allergic diseases.
pediatrics,immunology,allergy